Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.36 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.31 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.31 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | F7 | P08709 | 1/20 | 0.30 |
| ▸ | F3 | P13726 | 1/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2753388 | 0.79 | CNR2 (0.35) | NPC1RAB9A | |
| SCHEMBL5547319 | 0.79 | — | — | |
| SCHEMBL2753055 | 0.76 | JAK2 (0.37) | LMNA | |
| SCHEMBL2753728 | 0.76 | HTR7 (0.35) | NOS3NOS1NOS2 | |
| SCHEMBL4907036 | 0.75 | LMNA (0.35) | LMNA | |
| SCHEMBL5542344 | 0.73 | TAAR1 (0.44) | MAPK14 | |
| SCHEMBL2751582 | 0.72 | HTT (0.35) | — | |
| SCHEMBL2649168 | 0.72 | LMNA (0.58) | NPC1RAB9ALMNATTRCSNK1D | |
| SCHEMBL432470 | 0.71 | MAPK14 (0.38) | NPC1RAB9AMAPK14 | |
| SCHEMBL2751878 | 0.71 | CYP11B2 (0.43) | NPC1RAB9AMAPK14L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178540-B2 | Pyrimidylmethyl-sulfonamide compounds | BASF SE (DE) | 2012-05-15 | — | — | US | disclosed |
| US-20100077512-A1 | Pyridazin-4-ylmethyl-sulfonamides used as Fungicides and Against Arthropods | BASF SE (DE) | 2010-03-25 | — | — | US | disclosed |
| US-20100069243-A1 | Pyrimidylmethyl-Sulfonamide Compounds | BASF SE (DE) | 2010-03-18 | — | — | US | disclosed |
| EP-2066643-A1 | PYRIDAZIN-4-YLMETHYL-SULFONAMIDES USED AS FUNGICIDES AND AGAINST ARTHROPODS | BASF SE (DE) | 2009-06-10 | — | — | EP | disclosed |
| EP-2064190-A1 | PYRIMIDYLMETHYL-SULFONAMIDE COMPOUNDS USEFUL AS FUNGICIDES AND AGAINST ARTHROPODS | BASF SE (DE) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008062011-A1 | PYRIMIDYLMETHYL-SULFONAMIDE COMPOUNDS USEFUL AS FUNGICIDES AND AGAINST ARTHROPODS | BASF SE (DE) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008062012-A1 | PYRIDAZIN-4-YLMETHYL-SULFONAMIDES USED AS FUNGICIDES AND AGAINST ARTHROPODS | BASF SE (DE) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069243-A1 | Pyrimidylmethyl-Sulfonamide Compounds | TPMT, NISCH, PPA1 | NPC1 4195/4885RAB9A 2914/4885LMNA 4514/4885 |
| US-20100077512-A1 | Pyridazin-4-ylmethyl-sulfonamides used as Fungicides and Against Arthropods | PIR, PRDX4, PRDX2 | NPC1 4528/4885RAB9A 3677/4885LMNA 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.